Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion.

[primary effusion lymphoma]

In HIV-1 -infected patients a long lasting CD 4 + cell decline influences the host-EBV balance and thereby increases the risk for EBV related malignancies . In spite of a world-wide access to combination antiretroviral therapy (cART ) there are still a considerable number of HIV-1 -infected patients who will develop severe immunodeficiency . These undiagnosed HIV-1 infected patients , so called late testers , demonstrate an increased lymphoma risk , compared to patients diagnosed early . Consecutive individual screening for EBV DNA-load in late testers might be a useful predictor of emerging EBV-malignancy .Patient biopsies and ascites were analyzed morphologically , by immuncyto-histochemistry and in -situ hybridization . Viral DNA and RNA load were quantified by PCR . Cell lines from primary tumor and from ascites , were established in vitro and further analyzed .We here report on a case of EBV-positive lymphoma in an AIDS patient , first presenting with pleural effusion and ascites and was thus initially considered a primary effusion lymphoma (PEL ) but was later diagnosed as a plasmablastic lymphoma (PBL ). The patient had responded to cART with undetectable HIV-RNA and increased CD 4 cell count one year prior to lymphoma presentation . At the time of lymphoma diagnosis the HIV-RNA values were <50 RNA-copies per mL blood (undetectable ) and the CD 4 -positive cell count 170 ×106 /L . The lymphoma was CD 4 5 -negative and weakly CD 22 - and CD 30 -positive . The patient had a history of Kaposi sarcoma and HHV-8 seropositivity . The lymphoma biopsies , and three cell lines derived on different occasions from the tumor cell effusion , were all EBV-positive but HHV-8 negative .A noticeable EBV-DNA load decline was observed during the remission of the lymphoma following CHOP-therapy . The EBV-DNA load increased dramatically at the time of recurrence .EBV DNA load might be useful in monitoring the effect of lymphoma treatment as well as in estimating the risk of EBV-associated lymphoma in HIV-1 infected patients with pronounced immunosuppression .